{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:23:29Z","timestamp":1783697009869,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Allergology International"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.alit.2025.07.002","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T20:42:23Z","timestamp":1757364143000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical efficacy of mepolizumab and dupilumab for eosinophilic otitis media: Analysis of patient clinical characteristic"],"prefix":"10.1016","volume":"75","author":[{"given":"Saori","family":"Kikuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saemi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Iino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.alit.2025.07.002_bib1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.anl.2010.11.016","article-title":"Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease","volume":"38","author":"Iino","year":"2011","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.alit.2025.07.002_bib2","first-page":"112","article-title":"Epidemiologic surveillance of \u201ceosinophilic otitis media\u201d in Japan","volume":"14","author":"Suzuki","year":"2004","journal-title":"Otol Jpn"},{"key":"10.1016\/j.alit.2025.07.002_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000370122","article-title":"Eosinophilic otitis media is associated with asthma severity and smoking history","volume":"77","author":"Seo","year":"2025","journal-title":"ORL J Otorhinolaryngol Relat Spec"},{"key":"10.1016\/j.alit.2025.07.002_bib4","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/MAO.0000000000003850","article-title":"Improvement of suspected eosinophilic otitis media with targeted biolobic therapy","volume":"44","author":"Ryder","year":"2023","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.alit.2025.07.002_bib5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.alit.2019.02.004","article-title":"Severe asthma in Japan","volume":"68","author":"Nagase","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2025.07.002_bib6","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/MAO.0b013e318263d5b8","article-title":"Clinical efficacy of anti-IgE therapy for eosinophilic otitis media","volume":"33","author":"Iino","year":"2012","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.alit.2025.07.002_bib7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.anl.2018.07.011","article-title":"Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media","volume":"46","author":"Iino","year":"2019","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.alit.2025.07.002_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.anl.2018.05.007","article-title":"Successful treatment of eosinophilic otitis media associated with bronchial asthma with an anti-IL5 monoclonal antibody, mepolizumab","volume":"46","author":"Suzaki","year":"2019","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.alit.2025.07.002_bib9","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1097\/MAO.0000000000002493","article-title":"Use of IL-5 inhibitor benralizumab as a novel therapy for eosinophilic otitis media: clinical capsule and review of literature","volume":"41","author":"Chow","year":"2020","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.alit.2025.07.002_bib10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.anl.2020.09.001","article-title":"Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma","volume":"48","author":"Iino","year":"2021","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.alit.2025.07.002_bib11","article-title":"A case of severe asthma with eosinophilic otitis media successfully treated with anti-IgE monoclonal antibody omalizumab","volume":"2012","author":"Okude","year":"2012","journal-title":"Case Rep Pulmonol"},{"key":"10.1016\/j.alit.2025.07.002_bib12","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5152\/iao.2018.4517","article-title":"Eosinophilic otitis media treated with anti-IgE monoclonal antibodies and a bone conduction implant","volume":"14","author":"Han","year":"2018","journal-title":"J Int Adv Otol"},{"key":"10.1016\/j.alit.2025.07.002_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/02770903.2022.2033262","article-title":"Otitis media in severe asthma associated with chronic rhinosinusitis with nasal polyps: a new therapeutic target for biologics","volume":"60","author":"Bartier","year":"2023","journal-title":"J Asthma"},{"key":"10.1016\/j.alit.2025.07.002_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102032","article-title":"Characteristics of patients with severe asthma who experienced treatment failure with omalizumab","volume":"68","author":"Akaba","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.alit.2025.07.002_bib15","first-page":"57","article-title":"Dupilumab remarkably improved eustachian tube obstruction: a case of mepolizumab-resistant eosinophilic otitis media","volume":"33","author":"Takeshita","year":"2023","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.alit.2025.07.002_bib16","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.alit.2023.03.007","article-title":"Dupilumab improves eosinophilic otitis media associated with eosinophilic chronic rhinosinusitis","volume":"72","author":"Nakashima","year":"2023","journal-title":"Allergol Int"},{"key":"10.1016\/j.alit.2025.07.002_bib17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1081-1206(10)60967-2","article-title":"Effectiveness of instillation of triamcinolone acetonide into middle ear for eosinophilic otitis media associated with bronchial asthma","volume":"97","author":"Iino","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.alit.2025.07.002_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.anl.2014.08.003","article-title":"Risk factors associated with severity of eosinophilic otitis media","volume":"41","author":"Kanazawa","year":"2014","journal-title":"Auris Nasus Larynx"},{"issue":"Suppl","key":"10.1016\/j.alit.2025.07.002_bib19","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0194-5998(97)70005-6","article-title":"Staging for rhinosinusitis","volume":"117","author":"Lund","year":"1997","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.alit.2025.07.002_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.anl.2022.11.004","article-title":"Eosinophilic otitis media; state -of -the-art diagnosis and treatment","volume":"50","author":"Iino","year":"2023","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.alit.2025.07.002_bib21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): randomized, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2025.07.002_bib22","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind placebo-controlled, parallel-group phase 3 trails","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.alit.2025.07.002_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222011209","article-title":"IL13 may play an important role in developing eosinophilic chronic rhinosinusitis and eosinophilic otitis media with severe asthma","volume":"22","author":"Shimizu","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.alit.2025.07.002_bib24","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/lary.29730","article-title":"Complete remission of severe eosinophilic otitis media with dupilumab: a case report","volume":"131","author":"van der Lans","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.alit.2025.07.002_bib25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000091215","article-title":"Intractable otitis media with eosinophils: importance of diagnosis and validity of treatment for hearing preservation","volume":"68","author":"Nakagawa","year":"2006","journal-title":"ORL J Otorhinolaryngol Related Spec"},{"key":"10.1016\/j.alit.2025.07.002_bib26","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/MAO.0b013e318185fb0d","article-title":"Bone conduction hearing level in patients with eosinophilic otitis media associated with bronchial asthma","volume":"29","author":"Iino","year":"2008","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.alit.2025.07.002_bib27","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.anl.2020.08.001","article-title":"Risk factors for bacterial infection to cause sensorineural hearing loss in eosinophilic otitis media","volume":"48","author":"Masuda","year":"2021","journal-title":"Auris Nasus Larynx"},{"key":"10.1016\/j.alit.2025.07.002_bib28","article-title":"Japanese Society of Allergology","author":"Japanese Respiratory","year":"2020","journal-title":"[The Statement of the Appropriate Use of Biologics for Adult Bronchial Asthma](in Japanese); 2020."},{"key":"10.1016\/j.alit.2025.07.002_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizlumab for patients with severe asthma: pooled analysis of the SIROCCO and. CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2025.07.002_bib30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe secondary analysis of DREZM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.alit.2025.07.002_bib31","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.alit.2025.07.002_bib32","first-page":"838","article-title":"The role of periostin in eosinophilic otitis media","volume":"132","author":"Nishizawa","year":"2012","journal-title":"Acta Otolaryngol"},{"key":"10.1016\/j.alit.2025.07.002_bib33","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.anl.2020.05.014","article-title":"Periostin in middle ear mucosa according to eosinophilic otitis media severity: middle ear pathology-based treatment","volume":"47","author":"Esu","year":"2020","journal-title":"Auris Nasus Larynx"}],"container-title":["Allergology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025000814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1323893025000814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:07:07Z","timestamp":1767388027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1323893025000814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1323893025000814"],"URL":"https:\/\/doi.org\/10.1016\/j.alit.2025.07.002","relation":{},"ISSN":["1323-8930"],"issn-type":[{"value":"1323-8930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy of mepolizumab and dupilumab for eosinophilic otitis media: Analysis of patient clinical characteristic","name":"articletitle","label":"Article Title"},{"value":"Allergology International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.alit.2025.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Allergology. Published by Elsevier B.V\u00e9","name":"copyright","label":"Copyright"}]}}